GLP1R and obesity disorder: In contradistinction, the recently FDA-approved GLP1 receptor agonists Semaglutide (Wegovy) and Tirzepatide (Zepbound) are associated with average weight loss similar to that of bariatric surgery (i.e., ~15 to 25%) [9] with fewer side effects and possibly many other benefits beyond obesity [19].